Published in J Clin Oncol on May 01, 1994
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer (2008) 1.14
Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 1.06
Standard treatment of chemotherapy-induced emesis. Support Care Cancer (1997) 1.00
Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 0.90
Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience. Support Care Cancer (2015) 0.87
Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer (2003) 0.84
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist (2015) 0.83
Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Support Care Cancer (2015) 0.83
Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Support Care Cancer (2013) 0.81
Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer (1996) 0.79
Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer (2003) 0.79
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. J Gynecol Oncol (2015) 0.77
Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer. Ann Surg Treat Res (2014) 0.77
Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Cancer (1996) 0.76
Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. Int J Clin Exp Med (2015) 0.76
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. Med Klin (Munich) (1998) 0.75
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles? J Clin Oncol (1994) 0.75
A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol (2015) 0.75
Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer (2015) 0.75
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
Genome sequence of the plant pathogen Ralstonia solanacearum. Nature (2002) 6.23
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology (2008) 4.78
Familial Mediterranean fever. Lancet (1998) 4.16
Patient-to-patient transmission of HIV in private surgical consulting rooms. Lancet (1994) 4.12
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med (1974) 3.57
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
General practice audit of asthma in childhood. Br Med J (Clin Res Ed) (1984) 2.98
Surface localization of Helicobacter pylori urease and a heat shock protein homolog requires bacterial autolysis. Infect Immun (1996) 2.80
Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet (1995) 2.73
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Novel path to apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T lymphocytes evoke internucleosomal DNA degradation. Infect Immun (1994) 2.47
Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med (1994) 2.45
Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril (2001) 2.44
A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes. Med Microbiol Immunol (1993) 2.37
Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol (2001) 2.30
Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol (2005) 2.20
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol (1996) 2.11
Amplification and purification of UvrA, UvrB, and UvrC proteins of Escherichia coli. J Biol Chem (1985) 2.11
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J (1995) 2.08
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol (1985) 2.03
Boy Scouts of America policy on homosexuality. Arch Pediatr Adolesc Med (2001) 2.03
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev (2004) 1.92
Paracetamol overdose in Jerusalem, 1984-89. Isr J Med Sci (1992) 1.91
Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study. Lancet (2001) 1.90
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol (1990) 1.88
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation (1994) 1.80
Alport's syndrome. A report of 58 cases and a review of the literature. Am J Med (1981) 1.78
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer (2004) 1.76
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Human T-cell leukaemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. Lancet (1983) 1.69
Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer (1999) 1.68
Strategy for the detection of Helicobacter species by amplification of 16S rRNA genes and identification of H. felis in a human gastric biopsy. Res Microbiol (1997) 1.65
Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection (2009) 1.64
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol (2007) 1.63
Lawsonia intracellularis proliferative enteropathy in a weanling foal. Equine Vet J (1998) 1.63
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int (1975) 1.59
Adult paratesticular sarcomas: a review of 21 cases. J Urol (1991) 1.59
Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not in resistant cells. Proc Natl Acad Sci U S A (1997) 1.58
Impact of pretransplant renal function on survival after liver transplantation. Transplantation (1995) 1.58
Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breast. Cancer (1996) 1.57
VAMP-2 and cellubrevin are expressed in pancreatic beta-cells and are essential for Ca(2+)-but not for GTP gamma S-induced insulin secretion. EMBO J (1995) 1.56
H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int (1986) 1.55
Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst (1992) 1.55
Concentration by evaporation and the prebiotic synthesis of cytosine. Orig Life Evol Biosph (2001) 1.54
Risk factors for breast cancer. Am J Epidemiol (1983) 1.54
Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am J Hum Genet (2001) 1.54
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54
Characteristics of pregnant women who engage in binge alcohol consumption. CMAJ (1997) 1.53
Transmission of Creutzfeldt-Jakob disease by handling of dura mater. Lancet (1993) 1.52
Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf (2000) 1.51
Preoperative cyst fluid analysis is useful for the differential diagnosis of cystic lesions of the pancreas. Gastroenterology (1995) 1.51
Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. Intern Med J (2007) 1.50
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
Cervical lymph node biopsy--a study of its morbidity. J Laryngol Otol (1984) 1.49
Surgical removal of echocardiographically detected multiple pedunculated and mobile left ventricular thrombi in acute myocardial infarction. Isr J Med Sci (1989) 1.49
The relationship between abdominal aortic aneurysm wall compliance, maximum diameter and growth rate. Cardiovasc Surg (1999) 1.47
T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med (1991) 1.47
A relationship between apoptosis and flow during programmed capillary regression is revealed by vital analysis. Development (1996) 1.47
Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion. Thromb Res (1981) 1.44
A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology (1999) 1.43
Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med (2004) 1.42
Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet (1987) 1.42
Unscientific assertions on treating asthma in general practice. BMJ (1994) 1.41
Fatal transfusion reaction due to Yersinia enterocolitica. J Hosp Infect (1994) 1.40
Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf (2011) 1.39
Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration. J Pain Symptom Manage (1995) 1.39
Familial Mediterranean fever in the "Chuetas" of Mallorca--origin in inquisition? Isr J Med Sci (1995) 1.39